KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Inventory (2016 - 2025)

Travere Therapeutics' Inventory history spans 12 years, with the latest figure at $5.9 million for Q4 2025.

  • For Q4 2025, Inventory fell 5.24% year-over-year to $5.9 million; the TTM value through Dec 2025 reached $5.9 million, down 5.24%, while the annual FY2025 figure was $5.9 million, 5.24% down from the prior year.
  • Inventory reached $5.9 million in Q4 2025 per TVTX's latest filing, up from $5.5 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $20.8 million in Q3 2023 to a low of $3.9 million in Q1 2025.
  • Average Inventory over 5 years is $7.6 million, with a median of $6.6 million recorded in 2021.
  • Peak YoY movement for Inventory: surged 184.68% in 2023, then tumbled 69.4% in 2024.
  • A 5-year view of Inventory shows it stood at $7.3 million in 2021, then tumbled by 38.15% to $4.5 million in 2022, then soared by 108.05% to $9.4 million in 2023, then tumbled by 34.11% to $6.2 million in 2024, then dropped by 5.24% to $5.9 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Inventory are $5.9 million (Q4 2025), $5.5 million (Q3 2025), and $4.1 million (Q2 2025).